Amyotrophic Lateral Sclerosis (als) malady

NINDS: Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig's disease or classical motor neuron disease, is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells responsible for controlling voluntary muscles.³¹

MalaCards: Amyotrophic Lateral Sclerosis (als), also known as amyotrophic lateral sclerosis, is related to amyotrophic lateral sclerosis and frontotemporal dementia. An important gene associated with Amyotrophic Lateral Sclerosis (als) is NEFH (neurofilament, heavy polypeptide), and among its related pathways are Caspase Cascade and Endothelin-1 Signaling Pathway. The drug riluzole and the compounds egcg and sp 600125 have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, skin and b cells, and related mouse phenotypes are endocrine/exocrine gland and respiratory system.

amyotrophic lateral sclerosis (als) 31 amyotrophic lateral sclerosis 43

Disease types for amyotrophic lateral sclerosis family:

amyotrophic lateral sclerosis, type 4	amyotrophic lateral sclerosis type 2
amyotrophic lateral sclerosis type 10	amyotrophic lateral sclerosis type 11
amyotrophic lateral sclerosis type 3	amyotrophic lateral sclerosis type 5
amyotrophic lateral sclerosis type 6	amyotrophic lateral sclerosis type 7
amyotrophic lateral sclerosis type 8	amyotrophic lateral sclerosis type 9
amyotrophic lateral sclerosis (als)

Diseases related to amyotrophic lateral sclerosis (als) by text searches and GeneDecks gene sharing:

(show top 50)    (show all 612)

id	Related Disease	Score	Top Affiliating Genes
1	amyotrophic lateral sclerosis	40.4	DCTN1, PRPH, NEFH
2	frontotemporal dementia	34.3	CHMP2B, YWHAQ, BAX, FUS, ACHE, GFAP
3	motor neuron disease	33.3	CNTF, SETX, VEGFA, RAB5A, CHMP2B, CDK5
4	muscular atrophy	32.2	CNTF, BCL2, BCL2L1, BAD, IGHMBP2, HSPB8
5	spinal muscular atrophy	31.7	BCL2, BCL2L1, BAD, IGHMBP2, HSPB8, CASP3
6	tooth disease	31.5	CNTF, HSPB8, TOMM40, PRPH, NEFL, NEFM
7	charcot-marie-tooth disease	31.5	CNTF, HSPB8, TOMM40, PRPH, NEFL, NEFM
8	multiple system atrophy	31.2	RAB5A, CDK5, TNF, DRD2, GFAP, PVALB
9	parkinson's disease	30.7	CNTF, BAD, BAX, CDK5, GRIN2B, APAF1
10	paralysis	30.6	CNTF, SETX, FUS, FGGY, IGHMBP2, ALS2
11	neurodegenerative disease	30.5	CNTF, RAC1, BCL2, BCL2L1, UBQLN1, CDK5
12	macroglobulinemia	28.9	VEGFA, BCL2, BAX, TNF, CYCS
13	spasticity	28.9	VEGFA, RAC1, CDK5, MMP9, ALS2, CRP
14	dementia	28.8	VEGFA, BCL2, CHMP2B, YWHAQ, UBQLN1, BAX
15	amyloidosis	27.7	BCL2, MMP9, HSPB8, TP53, TNF, TNFRSF1A
16	breast cancer	27.6	VEGFA, BCL2, MMP2, MMP9, CASP8, TP53
17	blindness	27.5	CNTF, VEGFA, MMP9, MAPK14, CCL2, IGF1
18	neuropathy	26.1	CNTF, SETX, VEGFA, MMP2, MMP9, MAPK14
19	neurodegeneration	25.6	CNTF, VEGFA, BCL2, BCL2L1, UBQLN1, BAX
20	down syndrome	25.3	VEGFA, RAB5A, RAC1, BAX, MMP2, MMP9
21	lateral sclerosis	24.4	CNTF, SETX, VGF, VEGFA, RAB5A, RAC1
22	cervicitis	23.4	VEGFA, BID, BCL2, BCL2L1, BAX, CFLAR
23	multiple myeloma	22.5	CNTF, VEGFA, RAC1, BID, BCL2, BCL2L1
24	multiple sclerosis	22.1	CNTF, VEGFA, RAC1, BCL2, BCL2L1, BAX
25	neuronitis	22.1	CNTF, SETX, VGF, VEGFA, RAB5A, RAC1
26	myeloma	21.9	CNTF, VEGFA, RAC1, BID, BCL2, BCL2L1
27	alzheimer's disease	21.8	CNTF, VGF, VEGFA, RAB5A, RAC1, BID
28	schizophrenia	21.6	CNTF, VGF, VEGFA, BCL2, YWHAQ, MMP9
29	leukemia	21.5	CNTF, VEGFA, RAC1, BID, BCL2, BCL2L1
30	hypoxia	20.8	VEGFA, RAC1, BID, BCL2, BCL2L1, UBQLN1
31	prostatitis	20.1	CNTF, VEGFA, RAB5A, RAC1, BID, BCL2
32	neuroblastoma	19.7	CNTF, VGF, VEGFA, RAC1, BCL2, BCL2L1
33	cerebritis	19.7	CNTF, VEGFA, RAC1, BID, BCL2, BCL2L1
34	motor neuronopathy	13.9	CNTF, IGHMBP2, HSPB8, DCTN1
35	distal hereditary motor neuropathy	13.7	SETX, HSPB8, DCTN1, NEFL
36	progressive supranuclear palsy	13.6	CDK5, DRD2, ACHE, PVALB, NEFL
37	pick's disease	13.5	CASP3, ACHE, TARDBP, NEFH, NEFL, NEFM
38	charcot-marie-tooth neuropathy type 2	13.4	HSPB8, TNF, TOMM40, NEFL
39	hyperphenylalaninemia	13.4	CAT, NOS1, SOD1, NEFH
40	temporal lobe epilepsy	13.4	GRIN1, GRIN2B, GFAP, PVALB, SLC1A2
41	hypermethioninemia	13.3	CAT, ACHE, SOD1
42	cerebral hypoxia	13.3	CASP3, CASP9, NOS1
43	meningitis and encephalitis	13.3	CAT, CRP, SOD1
44	muckle-wells syndrome	13.2	CASP1, TNFRSF1A, CRP
45	thoracic cancer	13.2	CASP3, CASP8, CASP9
46	glycogen storage disease type ia	13.2	CAT, CRP, SOD1, HGF
47	proliferative vitreoretinopathy	13.2	MET, CCL2, GFAP, HGF
48	peripheral primitive neuroectodermal tumor	13.2	BCL2, BCL2L1, CASP3, CASP8, CASP9
49	talipes equinovarus	13.1	BID, BCL2, APAF1, CASP10, CASP3, CASP8
50	doxorubicin induced cardiomyopathy	13.1	BAX, MET, MAPK14, HGF

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 riluzole

MalaCards organs/tissues related to amyotrophic lateral sclerosis (als):

²²

MGI Mouse Phenotypes related to amyotrophic lateral sclerosis (als):

²⁵ (show all 24)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland phenotype	MP:0005379	10.3	CASP8, APAF1, CCS, VGF, FUS
2	respiratory system phenotype	MP:0005388	10.0	BID, IGHMBP2, HSPB8, DRD2, NOS1, ACHE
3	embryogenesis phenotype	MP:0005380	9.2	MET, RAC1, UPF1, YWHAQ, CFLAR, APAF1
4	hematopoietic system phenotype	MP:0005397	9.2	BID, BCL2, BCL2L1, BAD, CFLAR, MAP2K6
5	liver/biliary system phenotype	MP:0005370	9.1	SREBF1, DRD2, TP53, MAPK11, BID, VEGFA
6	renal/urinary system phenotype	MP:0005367	8.9	BAX, MET, CASP3, TNFRSF1B, DRD2, PPP3CA
7	no phenotypic analysis	MP:0003012	8.6	GRIN2B, TARDBP, ACHE, DRD2, TP53, VEGFA
8	normal phenotype	MP:0002873	8.6	PVALB, GRIA1, GRIA2, GRIN1, GRIN2C, MAPK12
9	integument phenotype	MP:0010771	8.3	VGF, RAC1, BCL2, CDK5, DRD2, TNFRSF1B
10	reproductive system phenotype	MP:0005389	7.9	BAD, CCS, CCL2, CASP1, APAF1, GRIA2
11	behavior/neurological phenotype	MP:0005386	7.8	DCTN1, SLC1A2, NEFH, NEFM, CNTF, GRIN2D
12	immune system phenotype	MP:0005387	7.6	PPP3CB, PPP3CA, DRD2, TNFRSF1A, TNF, TP53
13	adipose tissue phenotype	MP:0005375	7.4	DRD2, TNFRSF1B, TNFRSF1A, TNF, TP53, IGF1
14	nervous system phenotype	MP:0003631	7.0	ACHE, DAXX, DRD2, TNFRSF1B, TNFRSF1A, CASP9
15	digestive/alimentary phenotype	MP:0005381	6.6	TNF, BCL2, MAPK11, CCL2, GPX1, IGHMBP2
16	skeleton phenotype	MP:0005390	6.6	MMP9, MAPK14, MAPK11, IGF1, CASP3, TP53
17	tumorigenesis	MP:0002006	6.4	IGF1, DRD2, TNFRSF1B, MET, APAF1, MAPK14
18	mortality/aging	MP:0010768	6.2	CCL2, VGF, MAP6, MAPK11, MAP2K3, APAF1
19	vision/eye phenotype	MP:0005391	6.0	MET, VEGFA, BID, BCL2, BAX, MMP2
20	growth/size phenotype	MP:0005378	6.0	BAX, HGF, YWHAQ, BCL2L1, BCL2, RAC1
21	muscle phenotype	MP:0005369	5.1	IGHMBP2, IGF1, CCL2, MAPK11, MAPK14, CNTF
22	cardiovascular system phenotype	MP:0005385	4.0	HGF, SOD1, PRPH2, GFAP, NOS1, CRP
23	cellular phenotype	MP:0005384	2.9	DAXX, CYCS, PPP3CA, PPP3CB, GFAP, PPP3R1
24	homeostasis/metabolism phenotype	MP:0005376	2.7	NEFM, SOD1, TARDBP, IGF1, IGHMBP2, GPX1

Articles related to amyotrophic lateral sclerosis (als):

(show all 43)

id	Title	Authors	Year	Affiliating Genes
1	Vascular endothelial growth factor-A (VEGF-A) and che mokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients. (21569455)	Gupta P.K.... Anand A.	2011	VEGFA, CCL2
2	Sterol regulatory element binding protein-1 (SREBP1) activation in motor neurons in excitotoxicity and amyotrophic lateral sclerosis (ALS): Indip, a potential therapeutic peptide. (21871872)	Taghibiglou C.... Cashman N.R.	2011	SREBF1
3	Proteins that bind to misfolded mutant superoxide dis mutase-1 in spinal cords from transgenic amyotrophic lateral sclerosis (ALS) mo del mice. (21493711)	ZetterstrAPm P.... Marklund S.L.	2011	SOD1
4	Modification of superoxide dismutase 1 (SOD1) propert ies by a GFP tag--implications for research into amyotrophic lateral sclerosis (ALS). (20221404)	Stevens J.C.... Fisher E.M.	2010	SOD1
5	Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). (20352044)	Cox L.E.... Shaw P.J.	2010	CHMP2B
6	Ubiquilin modifies TDP-43 toxicity in a Drosophila mo del of amyotrophic lateral sclerosis (ALS). (20154090)	Hanson K.A.... Tibbetts R.S.	2010	TARDBP, UBQLN1
7	The small heat shock protein B8 (HspB8) promotes auto phagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). (20570967)	Crippa V.... Poletti A.	2010	SOD1, HSPB8
8	Significance of behavioural tests in a transgenic mou se model of amyotrophic lateral sclerosis (ALS). (20450936)	Knippenberg S.... Petri S.	2010	SOD1
9	Neuronal death in amyotrophic lateral sclerosis (ALS) : what can we learn from genetics? (20406185)	Sreedharan J.	2010	TARDBP
10	Proteome analysis reveals candidate markers of diseas e progression in amyotrophic lateral sclerosis (ALS). (19853641)	Brettschneider J.... Tumani H.	2010	NRAP
11	Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. (19112176)	Kim S.H.... Tibbetts R.S.	2009	TARDBP, UBQLN1
12	Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). (19523650)	Fang L.... Brettschneider J.	2009	MMP2, MMP9
13	A novel mouse model with impaired dynein/dynactin function develops amyotrophic lateral sclerosis (ALS)-like features in motor neurons and improves lifespan in SOD1-ALS mice. (18579581)	Teuling E.... Jaarsma D.	2008	SOD1
14	Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. (18432310)	Zhao Z.... Pasinetti G.M.	2008	VGF
15	Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. (18677636)	Goodall E.F.... Morrison K.E.	2008	CRP
16	Interaction of amyotrophic lateral sclerosis (ALS)-related mutant copper-zinc superoxide dismutase with the dynein-dynactin complex contributes to inclusion formation. (18515363)	Strom A.L.... Zhu H.	2008	SOD1
17	Pathogenesis and therapeutic perspectives for amyotrophic lateral sclerosis (ALS) (18210800)	Abe K.	2007	SOD1
18	Interaction between familial amyotrophic lateral sclerosis (ALS)-linked SOD1 mutants and the dynein complex. (17403682)	Zhang F.... Zhu H.	2007	SOD1
19	SOD1 gene mutations in Italian patients with Sporadic Amyotrophic Lateral Sclerosis (ALS). (16952453)	Corrado L.... Mazzini L.	2006	SOD1
20	O-glycosylation of the tail domain of neurofilament protein M in human neurons and in spinal cord tissue of a rat model of amyotrophic lateral sclerosis (ALS). (16006557)	Ludemann N.... Brandt R.	2005	NEFM
21	Increased internalisation and degradation of GLT-1 glial glutamate transporter in a cell model for familial amyotrophic lateral sclerosis (ALS). (15466883)	Vanoni C.... Pietrini G.	2004	SOD1, SLC1A2
22	VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). (15763997)	Terry P.D.... Taylor J.A.	2004	VEGFA
23	DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). (15106121)	Chen Y.-Z.... Chance P.F.	2004	IGHMBP2, UPF1, SETX
24	Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mutation. (12707786)	Kato S.... Ohama E.	2003	MET, HGF
25	Human CCS gene: genomic organization and exclusion as a candidate for amyotrophic lateral sclerosis (ALS). (11991808)	Silahtaroglu A.N.... Tumer Z.	2002	CCS
26	Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress. (12215229)	Cookson M.R.... Shaw P.J.	2002	SOD1
27	A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. (11465936)	Desnuelle C.... Favier A.	2001	SOD1
28	Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2. (11161814)	Hadano S.... Hayden M.R.	2001	CASP10, CASP8, CFLAR
29	Decreased striatal dopamine D2 receptor binding in amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA): D2 receptor down-regulation versus striatal cell degeneration. (11090866)	Vogels O.J.... Horstink M.W.	2000	DRD2
30	Cyclin dependent kinase-5 (CDK-5) phosphorylates neurofilament heavy (NF-H) chain to generate epitopes for antibodies that label neurofilament accumulations in amyotrophic lateral sclerosis (ALS) and is present in affected motor neurones in ALS. (10509378)	Bajaj N.P.... Miller C.C.	1999	CDK5
31	A yeast artificial chromosome-based physical map of the juvenile amyotrophic lateral sclerosis (ALS2) critical region on human chromosome 2q33-q34. (9889004)	Hadano S.... Hayden M.R.	1999	ALS2
32	Cytotoxic activity of serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients against acetylcholinesterase. (10464429)	NIEBROJ-DOBOSZ I.... Mickielewicz A.	1999	ACHE
33	Does the pathological factor in amyotrophic lateral sclerosis (ALS) damage also astrocytes? (9757619)	RafaA8owska J.... Podlecka A.	1998	GFAP
34	Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). (9875737)	Tomkins J.... Shaw P.J.	1998	NEFH
35	Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. (9207139)	Bruijn L.I.... Cleveland D.W.	1997	SOD1
36	Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients. (8883943)	DorAc S.... Quirion R.	1996	IGF1
37	A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. (8628460)		1996	CNTF
38	Differential abundance of glutamate transporter subty pes in amyotrophic lateral sclerosis (ALS)-vulnerable versus ALS-resistant brai n stem motor cell groups. (8934560)	Medina L.... Reiner A.	1996	PVALB
39	Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. (8860837)	Aebischer P.... de Tribolet N.	1996	CNTF
40	Detection by 4-parameter microscopic imaging and increase of rare mononuclear blood leukocyte types expressing the Fc gamma RIII receptor (CD16) for immunoglobulin G in human sporadic amyotrophic lateral sclerosis (ALS). (8570089)	Schubert W.... Schwan H.	1995	FCGR3B
41	A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. (8681312)		1995	CNTF
42	Deficiency of human ciliary neurotropic factor (CNTF) is not causally related to amyotrophic lateral sclerosis (ALS) (8752458)	Takahashi R.	1995	CNTF
43	Familial amyotrophic lateral sclerosis (ALS) in Japan associated with H46R mutation in Cu/Zn superoxide dismutase gene: a possible new subtype of familial ALS. (7836951)	Aoki M.... Abe K.	1994	SOD1

Genes related to amyotrophic lateral sclerosis (als) according to GeneCards:

(show top 50)    (show all 93)

id	Symbol	Description	Score	GeneCards Section Context
1	NEFH	neurofilament, heavy polypeptide	11.1	Pathways & Interactions, Publications, Summaries
2	SETX	senataxin	11.1	Publications, Summaries
3	GRIA2	glutamate receptor, ionotropic, AMPA 2	11.1	Summaries, Pathways & Interactions
4	LOC644462	amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2 pseudogene	11.0	Publications
5	CHP2	calcineurin-like EF hand protein 2	11.0	Pathways & Interactions
6	PPP3R2	protein phosphatase 3, regulatory subunit B, beta	11.0	Pathways & Interactions
7	PRPH	peripherin	11.0	Pathways & Interactions
8	CCS	copper chaperone for superoxide dismutase	11.0	Publications, Pathways & Interactions
9	VGF	VGF nerve growth factor inducible	11.0	Publications
10	NIF3L1	NIF3 NGG1 interacting factor 3-like 1 (S. cerevisiae)	11.0	Publications
11	NDUFB3	NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa	11.0	Publications
12	TOMM40L	translocase of outer mitochondrial membrane 40 homolog (yeast)-like	11.0	Pathways & Interactions
13	NEFM	neurofilament, medium polypeptide	11.0	Publications, Pathways & Interactions
14	DPP6	dipeptidyl-peptidase 6	11.0	UniProt Related
15	STRADB	STE20-related kinase adaptor beta	11.0	Publications
16	NEFL	neurofilament, light polypeptide	11.0	Pathways & Interactions
17	DERL1	derlin 1	11.0	Pathways & Interactions
18	GRIN2C	glutamate receptor, ionotropic, N-methyl D-aspartate 2C	11.0	Pathways & Interactions
19	HSPB8	heat shock 22kDa protein 8	11.0	Publications
20	CNTF	ciliary neurotrophic factor	11.0	Functions, Publications
21	CHMP2B	charged multivesicular body protein 2B	11.0	Publications
22	UBQLN1	ubiquilin 1	11.0	Publications
23	TOMM40	translocase of outer mitochondrial membrane 40 homolog (yeast)	11.0	Pathways & Interactions
24	MAPK12	mitogen-activated protein kinase 12	11.0	Pathways & Interactions
25	MAP6	microtubule-associated protein 6	11.0	Proteins
26	TRAK2	trafficking protein, kinesin binding 2	11.0	Publications
27	IGHMBP2	immunoglobulin mu binding protein 2	11.0	Publications
28	PPP3CB	protein phosphatase 3, catalytic subunit, beta isozyme	11.0	Pathways & Interactions
29	GRIN2D	glutamate receptor, ionotropic, N-methyl D-aspartate 2D	11.0	Pathways & Interactions
30	MAPK13	mitogen-activated protein kinase 13	11.0	Pathways & Interactions
31	DAXX	death-domain associated protein	11.0	Pathways & Interactions
32	FCGR3B	Fc fragment of IgG, low affinity IIIb, receptor (CD16b)	11.0	Publications
33	PRPH2	peripherin 2 (retinal degeneration, slow)	11.0	Pathways & Interactions
34	ALS2	amyotrophic lateral sclerosis 2 (juvenile)	11.0	Publications, Pathways & Interactions
35	NRAP	nebulin-related anchoring protein	11.0	Publications
36	CASP10	caspase 10, apoptosis-related cysteine peptidase	11.0	Publications
37	MAPK11	mitogen-activated protein kinase 11	11.0	Pathways & Interactions
38	BAD	BCL2-associated agonist of cell death	11.0	Pathways & Interactions
39	YWHAQ	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide	11.0	Expressions
40	SREBF1	sterol regulatory element binding transcription factor 1	11.0	Publications
41	RAB5A	RAB5A, member RAS oncogene family	11.0	Pathways & Interactions
42	GPX1	glutathione peroxidase 1	11.0	Pathways & Interactions
43	PVALB	parvalbumin	11.0	Publications
44	DCTN1	dynactin 1	11.0
45	TARDBP	TAR DNA binding protein	11.0	Publications
46	PPP3R1	protein phosphatase 3, regulatory subunit B, alpha	11.0	Pathways & Interactions
47	PPP3CC	protein phosphatase 3, catalytic subunit, gamma isozyme	11.0	Pathways & Interactions
48	UPF1	UPF1 regulator of nonsense transcripts homolog (yeast)	11.0	Publications
49	GRIN1	glutamate receptor, ionotropic, N-methyl D-aspartate 1	11.0	Pathways & Interactions
50	SLC1A2	solute carrier family 1 (glial high affinity glutamate transporter), member 2	11.0	Publications, Pathways & Interactions

Pathways related to amyotrophic lateral sclerosis (als) according to GeneDecks:

(show top 50)    (show all 297)

id	Pathway	Score	Top Affiliating Genes
1	Caspase Cascade36	10.2	DAXX, TNFRSF1B, TNFRSF1A, CASP1, CASP10, APAF1
2	Endothelin-1 Signaling Pathway36	10.0	CASP3, CASP1, NOS1
3	nNOS Signaling at Neuronal Synapses36	9.8	NOS1, PPP3CC, PPP3R1, PPP3R2, PPP3CB, PPP3CA
4	Neurophysiological process_Glutamate regulation of Dopamine D1A receptor signaling41	9.7	PPP3CC, PPP3R1, CDK5, GRIA1, GRIA2, PPP3R2
5	Neurophysiological process Glutamate regulation of Dopamine D1A receptor signaling10	9.7	PPP3CC, PPP3R1, PPP3R2, PPP3CB, PPP3CA, GRIN2D
6	Fas Signaling36	9.3	CFLAR, APAF1, MAP3K5, CASP10, CASP3, CASP1
7	Nur77 Signaling in T-Cell36	9.3	BCL2, PPP3CC, PPP3R1, PPP3R2, PPP3CB, PPP3CA
8	Long-term potentiation20	9.3	GRIN1, GRIA2, GRIA1, CHP1, CHP2, GRIN2A
9	Apoptosis and survival Regulation of Apoptosis by Mitochondrial Proteins10	9.3	BAD, CYCS, BAX, BCL2L1, BID, APAF1
10	Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins41	9.2	CASP9, TNFRSF1A, BID, CASP8, APAF1, BAX
11	IL-2 Pathway36	9.2	PPP3CC, PPP3R1, PPP3R2, PPP3CB, PPP3CA, MAPK11
12	Glutamatergic synapse20	9.2	GRIN2B, GRIN2A, GRIN1, GRIA2, GRIA1, CHP1
13	BAD Phosphorylation36	9.1	PPP3CB, PPP3R2, PPP3R1, PPP3CC, PPP3CA, BCL2
14	Apoptosis and survival_FAS signaling cascades41	9.1	BID, BCL2, BAX, CFLAR, CYCS, DAXX
15	Apoptosis and survival FAS signaling cascades10	9.1	CYCS, DAXX, CASP9, CASP8, CASP3, CASP10
16	VEGF signaling pathway20	8.9	VEGFA, RAC1, CHP2, CHP1, BAD, MAPK12
17	14-3-3 and Regulation of BAD Activity36	8.9	TNFRSF1B, TNFRSF1A, TNF, CASP3, MAP3K5, BAX
18	Dopamine-DARPP32 Feedback onto cAMP Pathway36	8.8	GRIA1, DRD2, GRIN1, GRIN2A, GRIN2B, GRIN2C
19	UVA-Induced MAPK Signaling36	8.8	MAPK13, MAPK12, BCL2L1, MAPK14, CASP3, CASP8
20	TRAF Pathway36	8.7	MAPK11, MAPK14, CASP3, MAPK12, MAP2K6, CASP8
21	SUMO Pathway36	8.6	TNFRSF1B, TNFRSF1A, DAXX, MAPK11, MAP2K6, TNF
22	Apoptosis and survival_Apoptotic TNF-family pathways41	8.6	BCL2L1, BCL2, BID, BAX, CASP10, CASP3
23	TNF Superfamily Pathway36	8.6	MAP2K6, TNFRSF1B, TNFRSF1A, TNF, CASP8, CASP1
24	Apoptosis and survival Apoptotic TNF-family pathways10	8.6	CASP10, BAX, BCL2L1, BCL2, BID, CASP3
25	Apoptosis and survival_TNFR1 signaling pathway41	8.5	CASP10, APAF1, CFLAR, BAX, BCL2, BID
26	Apoptosis and survival TNFR1 signaling pathway10	8.5	CASP10, CFLAR, BAX, BCL2, BID, CASP3
27	Apoptosis and Autophagy3	8.5	DAXX, TNFRSF1B, TNFRSF1A, BID, BCL2, BCL2L1
28	Apoptosis and survival_Caspase cascade41	8.5	CYCS, BID, BAX, TNFRSF1A, TNF, CASP9
29	Apoptosis and survival Caspase cascade10	8.5	TNFRSF1A, TNF, CASP9, CASP8, CASP3, CASP10
30	TNF Signaling36	8.5	CYCS, TNFRSF1B, TNFRSF1A, TNF, CASP9, CASP8
31	TNF-Induced Apoptosis Implicating Sphingolipids36	8.4	BAD, CASP3, CASP10, MAPK11, MAPK14, MAPK13
32	p53 Signaling36	8.4	BCL2, MAPK12, MAPK13, MAPK11, CASP3, CASP10
33	Toxoplasmosis20	8.3	BCL2, BCL2L1, BAD, MAP2K6, MAP2K3, MAPK12
34	DHA Signaling36	8.1	BID, BCL2, BCL2L1, YWHAQ, BAD, BAX
35	Pathogenesis of ALS36	7.9	TP53, BAD, BCL2L1, BCL2, BAX, GRIA1
36	14-3-3 Induced Apoptosis36	7.8	BID, BCL2, YWHAQ, BAD, MAPK12, MAPK13
37	Apoptotic Pathways Triggered By HIV136	7.8	TNF, TP53, CASP9, CASP3, MAP3K5, APAF1
38	STAT3 Pathway36	7.8	BAX, BCL2, MAP2K6, RAC1, MAP2K3, MAPK14
39	Molecular Mechanisms of Cancer36	7.8	APAF1, MAP2K3, MAPK13, MAP3K5, CASP3, CASP8
40	Apoptosis through Death Receptors36	7.7	CFLAR, BAX, BCL2, BID, APAF1, MAP3K5
41	Apoptosis Signaling Pathways37	7.6	BCL2L1, YWHAQ, BAD, BAX, APAF1, CASP10
42	MAPK Family Pathway36	7.5	MAPK14, MAPK13, MAPK12, MAP2K3, MAP2K6, BAX
43	MAPK signaling pathway20	7.5	PPP3CC, PPP3R1, PPP3R2, PPP3CB, PPP3CA, MAP2K6
44	Alzheimers disease20	7.4	CYCS, TNFRSF1A, TNF, CASP9, CASP8, CASP3
45	Pathways in cancer20	7.1	BAX, BAD, BCL2L1, BCL2, RAC1, VEGFA
46	Tuberculosis20	7.0	BCL2, RAB5A, CYCS, PPP3CA, PPP3CB, PPP3R2
47	Cellular Apoptosis Pathway36	6.9	CYCS, HGF, DAXX, TNFRSF1A, BID, BCL2
48	Apoptosis20	6.7	BID, PPP3R1, PPP3CC, PPP3R2, PPP3CB, BCL2
49	p38 Signaling36	6.5	DAXX, MAPK11, MAP3K5, CCL2, IGF1, MAPK14
50	Amyotrophic lateral sclerosis (ALS)20	4.3	GRIN2D, BCL2, BID, RAC1, RAB5A, BCL2L1

Compounds related to amyotrophic lateral sclerosis (als) according to GeneDecks:

(show top 50)    (show all 266)

id	Compound	Score	Top Affiliating Genes
1	egcg32	9.8	BCL2L1, SOD1, CYCS, CASP9, CAT, MAPK14
2	sp 60012532 42	10.6	CYCS, TP53, CASP3, BID
3	n acetylcysteine32	9.3	HGF, TP53, MAP3K5, MMP9, MMP2, CDK5
4	h2o232	9.2	APAF1, FCGR3B, CDK5, BAD, CNTF, MAPK14
5	phosphatidylserine32 9 9	11.2	BCL2, APAF1, CYCS, CASP9, CASP8, CASP1
6	mg 13232 42	10.2	BID, BCL2L1, BAX, CFLAR, HGF, CYCS
7	ceramide32	9.2	SREBF1, CYCS, TNF, CASP9, CASP8, CASP1
8	bongkrekic acid32	9.1	CASP9, CASP8, CAT, CASP3, BAX, BCL2L1
9	sanguinarine32	8.8	CYCS, CASP9, CASP8, BID, BCL2, BCL2L1
10	c2ceramide32	8.7	BCL2L1, BAX, MAPK14, CASP3, CASP8, TNF
11	noxa32	8.4	CYCS, TP53, CASP9, CASP8, CASP3, APAF1
12	nmda32 42	9.3	HGF, NEFL, SLC1A2, PVALB, GRIA2, GRIA1
13	cd 43732	8.3	CYCS, TP53, BID, BCL2, BCL2L1, BAX
14	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide32	8.2	MAPK14, CYCS, BCL2L1, BAX, MMP2, MMP9
15	suberoylanilide hydroxamic acid32	8.2	BCL2, BCL2L1, BAX, CFLAR, MAPK14, CASP3
16	dutp32	8.2	TNFRSF1A, TP53, CASP9, CASP8, CASP1, CASP3
17	adpribose32	8.0	BID, BCL2L1, BAX, APAF1, CYCS, TNF
18	z-vad-fmk32 42	9.0	CASP10, MAPK14, BAX, BCL2L1, BCL2, CASP3
19	nitric oxide32 9 18 9	11.0	MAP2K3, MAP3K5, GPX1, CASP1, GRIN2B, GRIN1
20	flavopiridol32 9 9	10.0	CASP8, CASP3, MAPK14, CDK5, CFLAR, BAX
21	bortezomib32 9 9	10.0	APAF1, CFLAR, BAX, BCL2L1, BCL2, BID
22	diphenyleneiodonium32	7.9	CASP3, CCL2, RAC1, TNF, VEGFA, CAT
23	parthenolide32	7.8	CYCS, BID, TNF, TP53, CASP9, CASP8
24	etoposide32 42 9 9	10.7	CASP3, APAF1, MMP2, CFLAR, BAX, BCL2L1
25	calcium32 9 18 9	10.7	FCGR3B, TNFRSF1A, CASP1, GPX1, GRIN2D, MAP3K5
26	adriamycin32	7.6	CASP8, CASP9, BAX, HGF, CASP1, CASP3
27	cysteine32	7.6	CASP9, SLC1A2, GFAP, NOS1, SREBF1, CYCS
28	triptolide32	7.4	BAX, VEGFA, BCL2, MAPK14, CCL2, CASP3
29	ly29400232	7.4	CRP, TNFRSF1B, MMP2, MMP9, MAPK14, MAPK11
30	oxygen32 18	8.3	BAD, GFAP, NOS1, CYCS, CASP9, CASP8
31	lactacystin32	7.3	MAPK14, CASP3, CASP8, CASP9, TP53, TNF
32	resveratrol32 9 18 9	10.2	SOD1, BCL2, BID, VEGFA, BCL2L1, BAX
33	wortmannin32 42	8.1	MMP9, MMP2, CFLAR, BAX, BAD, BCL2L1
34	arsenite32 18	8.0	CASP3, MAPK11, MAPK14, MAP2K3, MAP2K6, MMP9
35	paclitaxel32 34 9 9	9.9	HGF, GFAP, CYCS, TNFRSF1A, TP53, CASP9
36	doxorubicin32 34 9 9	9.8	HGF, CYCS, MET, CFLAR, BAX, BAD
37	sb 20358032 42	7.7	MMP2, BCL2L1, BCL2, RAC1, VEGFA, MMP9
38	superoxide32 18	7.7	NOS1, CCL2, MAP3K5, MAPK14, APAF1, FCGR3B
39	cisplatin32 34 9 9	9.3	CASP1, RAC1, VEGFA, BID, BCL2, BCL2L1
40	vegf32	6.3	HGF, MAP2K6, APAF1, MET, MMP9, CFLAR
41	pdtc32	6.3	HGF, SOD1, NOS1, CYCS, TNF, TP53
42	tyrosine32	6.3	HGF, NEFH, PVALB, GFAP, SREBF1, TNFRSF1B
43	phosphatidylinositol32	6.3	BCL2, MAP3K5, MAPK11, MAPK14, APAF1, FCGR3B
44	curcumin32	6.2	TNFRSF1A, TNF, TP53, CASP9, CASP8, CAT
45	genistein32 9 18 9	9.2	GFAP, NOS1, TNF, CASP9, CASP3, IGF1
46	pd 98,05932	6.1	BCL2L1, BCL2, BID, RAC1, CNTF, BAD
47	actinomycin d32	5.5	HGF, CYCS, TNFRSF1B, TNFRSF1A, TNF, TP53
48	retinoic acid32 42 18	7.3	IGF1, BCL2, RAC1, CNTF, BCL2L1, BAD
49	cycloheximide32	4.1	HGF, GFAP, NOS1, CRP, CYCS, TNFRSF1B
50	serine32	3.7	GRIA1, CNTF, RAC1, MET, MMP9, MMP2

Cellular components related to amyotrophic lateral sclerosis (als) according to GeneDecks:

(show all 18)

id	Name	GO ID	Score	Top Affiliating Genes
1	neurofilament	GO:005883	10.7	NEFH, PRPH, NEFL, NEFM
2	N-methyl-D-aspartate selective glutamate receptor complex	GO:017146	10.3	GRIN2C, GRIN2B, GRIN1, GRIN2A, GRIN2D
3	calcineurin complex	GO:005955	10.3	PPP3CA, PPP3CB, PPP3R1
4	outer membrane-bounded periplasmic space	GO:030288	10.3	GRIN2C, GRIN2A, GRIN2B, GRIN2D, GRIN1
5	synaptic cleft	GO:043083	10.2	GRIN1, GRIN2B, ACHE
6	axon	GO:030424	10.2	CDK5, CNTF, IGHMBP2, ALS2, TNFRSF1A, DRD2
7	pore complex	GO:046930	10.1	BCL2, BAX, TOMM40, TOMM40L
8	terminal button	GO:043195	9.8	GRIA2, GRIN1, GRIN2A, GRIN2B
9	postsynaptic membrane	GO:045211	9.8	GRIN2B, GRIN2C, GRIN2A, GRIN1, GRIA1, MET
10	postsynaptic density	GO:014069	9.7	ALS2, GRIN2C, DRD2, GRIN2B, GRIN2A, GRIN1
11	mitochondrial outer membrane	GO:005741	9.6	TOMM40L, BID, BAX, CASP8, BCL2L1, BCL2
12	neuronal cell body	GO:043025	9.6	SOD1, PRPH, ALS2, CCL2, GRIA1, CDK5
13	cell junction	GO:030054	9.5	GRIN1, CDK5, GRIA1, GRIA2, GRIN2C, GRIN2D
14	protein complex	GO:043234	9.2	TNFRSF1A, TOMM40L, UBQLN1, MMP9, ALS2, TP53
15	mitochondrion	GO:005739	8.1	NIF3L1, BAD, MAPK12, BCL2, MAPK14, TP53
16	extracellular space	GO:005615	7.2	TNF, IGF1, CCL2, MET, MMP9, VEGFA
17	cytoplasm	GO:005737	5.6	CFLAR, MET, FUS, DAXX, PPP3CA, NOS1
18	cytosol	GO:005829	5.3	BAX, CYCS, DAXX, TP53, CASP9, CASP8

Biological processes related to amyotrophic lateral sclerosis (als) according to GeneDecks:

(show top 50)    (show all 63)

id	Name	GO ID	Score	Top Affiliating Genes
1	neurofilament cytoskeleton organization	GO:060052	10.6	NEFM, NEFH, SOD1
2	cellular response to lipid	GO:071396	10.5	BAD, GRIN2A, GRIN2B
3	synaptic transmission, glutamatergic	GO:035249	10.5	ALS2, CDK5, GRIN1, GRIN2D
4	regulation of excitatory postsynaptic membrane potential	GO:060079	10.3	GRIN2C, GRIN2B, GRIN2A, GRIN1, CDK5
5	startle response	GO:001964	10.3	GRIN2A, GRIN2B, GRIN2D
6	response to amphetamine	GO:001975	10.2	DRD2, GRIN2B, GRIN2A, PPP3CB, GRIN1, SOD1
7	regulation of long-term neuronal synaptic plasticity	GO:048169	10.2	GRIN1, GRIN2A, GRIN2B, DRD2
8	long-term memory	GO:007616	10.1	GRIN1, GRIN2B, DRD2, GRIA1
9	regulation of mitochondrial membrane potential	GO:051881	10.1	BCL2L1, BAX, SOD1, BCL2
10	ovarian follicle development	GO:001541	10.1	BAX, SOD1, BCL2L1, VGF, BCL2
11	myoblast proliferation	GO:051450	10.1	GPX1, MET, IGF1, HGF
12	positive regulation of muscle cell differentiation	GO:051149	10.0	MAPK11, MAPK14, MAPK12, MAP2K6
13	nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway	GO:035872	10.0	CASP8, BCL2, MAP2K6, BCL2L1, CASP1
14	cell death	GO:008219	10.0	IGHMBP2, SETX, BCL2, FUS, ALS2, FGGY
15	negative regulation of neuron apoptotic process	GO:043524	9.9	BAX, BCL2L1, SOD1, BCL2, GRIN1, CNTF
16	activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c	GO:008635	9.9	CYCS, CASP3, BAX, APAF1, CASP9
17	extrinsic apoptotic signaling pathway	GO:097191	9.9	CASP8, BAD, TNF
18	peptidyl-serine phosphorylation	GO:018105	9.9	MAPK14, MAPK13, MAPK12, CDK5, BCL2
19	response to fungicide	GO:060992	9.8	GRIA2, GRIN2A, GRIN2B
20	apoptotic DNA fragmentation	GO:006309	9.8	SOD1, CASP3, BAX, CYCS
21	activation of pro-apoptotic gene products	GO:008633	9.8	BID, CASP8, CDK5, BAX, PPP3CC, BAD
22	cellular response to organic substance	GO:071310	9.8	CASP1, BAX, BCL2, CASP3
23	synaptic transmission	GO:007268	9.8	GRIN2C, GRIN2D, ACHE, SLC1A2, NEFL, GRIA2
24	induction of apoptosis via death domain receptors	GO:008625	9.8	BID, CASP3, DAXX, TNF
25	protein localization	GO:008104	9.8	TP53, GRIN2A, GRIN2C, DRD2, ALS2
26	cellular response to growth factor stimulus	GO:071363	9.8	MET, GRIN2A, MAPK14, CAT, GRIN2B
27	positive regulation of release of cytochrome c from mitochondria	GO:090200	9.8	BAX, BAD, TP53, BID
28	nerve growth factor receptor signaling pathway	GO:048011	9.7	CASP3, RAC1, MAPK11, MAPK12, MAPK13, MAPK14
29	response to wounding	GO:009611	9.7	CASP3, GRIN2C, GRIN2A, ACHE, MET, RAC1
30	regulation of mitochondrial membrane permeability	GO:046902	9.7	BAD, BID, BCL2, BCL2L1, TP53
31	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	9.6	BAD, BAX, TNF, CASP8, CASP1, MAP3K5
32	response to heat	GO:009408	9.6	BCL2, CCL2, SOD1, NOS1, MMP9
33	response to toxin	GO:009636	9.6	DRD2, CASP1, GPX1, BAX, BCL2
34	cellular response to amino acid stimulus	GO:071230	9.5	GRIN2A, BCL2L1, TNF, GRIN2B
35	positive regulation of neuron apoptotic process	GO:043525	9.5	TNF, BAX, CDK5, CASP9, CASP3
36	innate immune response	GO:045087	9.5	MAPK11, MAP3K5, CASP1, CASP8, BCL2, CASP10
37	Ras protein signal transduction	GO:007265	9.4	MAPK14, MAPK12, MAPK13, IGF1, TP53, MAPK11
38	activation of MAPK activity	GO:000187	9.4	MET, MAPK11, MAP2K6, MAP2K3, MAPK14, SOD1
39	cell aging	GO:007569	9.4	BCL2, MET, TP53, SOD1
40	response to gamma radiation	GO:010332	9.3	TP53, BAX, GPX1, CCL2, BCL2
41	response to ethanol	GO:045471	9.2	SOD1, TNFRSF1A, BCL2, GRIN1, MMP9, GRIN2A
42	neuron apoptotic process	GO:051402	9.2	CASP3, TP53, BCL2, BID, CDK5, BAX
43	release of cytochrome c from mitochondria	GO:001836	9.1	CASP3, BCL2L1, BCL2, BID, BAX, TP53
44	induction of apoptosis by extracellular signals	GO:008624	9.1	TNF, TNFRSF1A, CASP8, CASP3, MAP3K5, CFLAR
45	anti-apoptosis	GO:006916	8.7	STRADB, SOD1, CFLAR, HGF, BCL2, BCL2L1
46	response to drug	GO:042493	8.7	MET, MMP9, BCL2, GRIN2A, MAP2K6, CCL2
47	positive regulation of apoptotic process	GO:043065	8.5	GRIN2A, GRIN1, MMP9, BAX, BAD, BID
48	induction of apoptosis by intracellular signals	GO:008629	8.4	BCL2L1, BCL2, BID, PPP3CC, TP53, PPP3R1
49	response to hypoxia	GO:001666	7.8	TNF, NOS1, DRD2, TNFRSF1A, CASP1, MMP9
50	apoptotic process	GO:006915	6.8	CASP3, CASP1, CASP8, CASP9, TNF, TNFRSF1A

Molecular functions related to amyotrophic lateral sclerosis (als) according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	MAP kinase activity	GO:004707	10.2	MAPK14, MAPK11, MAPK12, MAPK13
2	neurotransmitter binding	GO:042165	10.2	GRIN1, GRIN2A, GRIN2B, GRIN2D
3	N-methyl-D-aspartate selective glutamate receptor activity	GO:004972	10.2	GRIN2C, GRIN1, GRIN2A, GRIN2B, GRIN2D
4	cysteine-type endopeptidase activator activity involved in apoptotic process	GO:008656	10.2	BAD, APAF1, MAP3K5, CASP1
5	extracellular-glutamate-gated ion channel activity	GO:005234	10.0	GRIA2, GRIN2D, GRIN2C, GRIN2B, GRIN2A, GRIN1
6	BH3 domain binding	GO:051434	9.9	BCL2, BCL2L1, BAX
7	glutamate binding	GO:016595	9.9	GRIN1, GRIN2A, GRIN2D
8	cysteine-type endopeptidase activity	GO:004197	9.8	CASP10, CASP3, CASP1, CASP8, CASP9, CFLAR
9	calmodulin binding	GO:005516	9.7	PPP3CC, PPP3R1, PPP3CB, PPP3CA, NOS1, MAP6
10	protein kinase binding	GO:019901	9.2	GRIN2A, TP53, MAP2K6, MAP2K3, MAP3K5, BCL2L1
11	enzyme binding	GO:019899	9.1	PPP3CB, CAT, CCS, RAC1, TRAK2, TP53
12	protein heterodimerization activity	GO:046982	8.5	VEGFA, BCL2, BCL2L1, BAD, MET, GRIN2B
13	protein binding	GO:005515	1.8	TRAK2, GRIN2B, GRIN2A, GRIN1, GRIA1, MET